Enhancing the Quality of Rivaroxaban Exposure Estima the Absence of Pharmacokinetic Sampling

CPT: Pharmacometrics and Systems Pharmacology

8, 805-814

DOI: 10.1002/psp4.12444

Citation Report

#	Article	IF	Citations
1	Rivaroxaban Precision Dosing Strategy for Real-World Atrial Fibrillation Patients. Clinical and Translational Science, 2020, 13, 777-784.	4.1	15
2	Associations Between Model-Predicted Rivaroxaban Exposure and Patient Characteristics and Efficacy and Safety Outcomes in the Treatment of Venous Thromboembolism. Journal of Thrombosis and Thrombolysis, 2020, 50, 1-11.	2.2	14
3	Associations Between Model-Predicted Rivaroxaban Exposure and Patient Characteristics and Efficacy and Safety Outcomes in Patients With Non-Valvular Atrial Fibrillation. Journal of Thrombosis and Thrombolysis, 2020, 50, 20-29.	2.2	17
4	Associations Between Model-Predicted Rivaroxaban Exposure and Patient Characteristics and Efficacy and Safety Outcomes in the Prevention of Venous Thromboembolism. Journal of Thrombosis and Thrombolysis, 2020, 50, 12-19.	2.2	9
5	Should We Monitor the Direct Oral Anticoagulants?. Journal of Thrombosis and Thrombolysis, 2020, 50, 30-32.	2.2	4
6	Alkaloidal Extract From Carica papaya Seeds Ameliorates CCl4-Induced Hepatocellular Carcinoma in Rats. Heliyon, 2021, 7, e07849.	4.8	11
7	Association of Sex With Stroke and Bleeding Risk of Apixaban and Rivaroxaban in Elderly Atrial Fibrillation Patients Using Propensity Score Weights. CJC Open, 2022, 4, 56-64.	1.8	8
8	Diagnostic Performances of D-Dimer, Prothrombin Time, and Red Blood Cell Distribution Width for Coronary Artery Lesion in Children With Acute Stage Kawasaki Disease. Frontiers in Pediatrics, 2023, 11, 1141158.	2.4	4